Pioglitazone Hydrochloride/Metformin Hydrochloride

盐酸吡格列酮/盐酸二甲双胍

Report date: 2022/08/16 20:00:19

Base Information

Drug NamePioglitazone Hydrochloride/Metformin Hydrochloride
Drug Alias NamePioglitazone/Metformin盐酸吡格列酮•盐酸二甲双胍吡格列酮/二甲双胍Pioglitazone Hydrochloride and Metformin HydrochloridePioglitazone/Metformin Hydrochloride +[11] 
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsPeroxisome proliferator-activated receptor γ agonists
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Peroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2Oropharyngeal NeoplasmsLeukoplakia, Oral +[6] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2005/08/29
Country/TerritoryUnited StatesEUMainland China +[4] 
CombinationsYes Metformin HydrochloridePioglitazone Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals USA IncUniversity Of MinnesotaCheplapharm Arzneimittel Gmbh +[5] 
Inactive CompaniesNational Cancer Institute
Active IndicationsDiabetes Mellitus, Type 2Leukoplakia, Oral
Inactive IndicationsOropharyngeal NeoplasmsMouth NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 

Other Information

ATC CodeA10BD05
Related LinksKEGG